Guthrie Susan, Pollitt Alexandra, Hanney Stephen, Grant Jonathan
Rand Health Q. 2014 Jun 1;4(2):16. eCollection 2014 Summer.
In 2012, RAND Europe and the Health Economics Research Group (Brunel University) were commissioned by the Wellcome Trust, Cancer Research UK, the National Institute for Health Research and the Academy of Medical Science to conduct a study of the returns to the public/charitable investment in cancer-related research. This study built on previous work published in the 2008 "What's it worth?" report that estimated the economic returns to medical research in terms of spillover benefits and health gain. The 2008 study was extensively quoted and cited as a clear justification for the economic importance of medical research and appears to have played a role in achieving the protection of the medical science budget in the recent public expenditure cuts. This cancer study used a similar approach to that used in the previous study, but with some methodological developments. One of the methodological developments was the inclusion of case studies to examine the validity and variability of the estimates on elapsed time between funding and health gains, and the amount of health gains that can be attributed to UK research. This study provides the full text of the five case studies conducted as well as some discussion of observations emerging across the case study set.
2012年，兰德欧洲公司与健康经济学研究小组（布鲁内尔大学）受惠康信托基金会、英国癌症研究中心、英国国家卫生研究院和医学科学院委托，对癌症相关研究的公共/慈善投资回报进行了一项研究。这项研究建立在2008年发表的《价值几何？》报告的先前工作基础之上，该报告从溢出效益和健康收益方面估计了医学研究的经济回报。2008年的研究被广泛引用，被视为医学研究经济重要性的明确理由，并且似乎在近期公共支出削减中保护医学科学预算方面发挥了作用。这项癌症研究采用了与先前研究类似的方法，但在方法上有一些改进。方法改进之一是纳入案例研究，以检验资助与健康收益之间的时间间隔估计以及可归因于英国研究的健康收益量估计的有效性和变异性。本研究提供了所进行的五个案例研究的全文以及对整个案例研究集所出现观察结果的一些讨论。
